Atria Wealth Solutions Inc. Has $11.93 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Atria Wealth Solutions Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,753 shares of the medical research company's stock after acquiring an additional 1,451 shares during the period. Atria Wealth Solutions Inc.'s holdings in Amgen were worth $11,925,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter worth about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter worth about $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen in the 4th quarter valued at approximately $36,000. PrairieView Partners LLC raised its position in Amgen by 118.3% in the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company's stock valued at $46,000 after buying an additional 97 shares during the last quarter. Finally, Wingate Wealth Advisors Inc. bought a new stake in Amgen in the 4th quarter valued at approximately $52,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent research reports. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a "peer perform" rating on the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Wells Fargo & Company decreased their price objective on Amgen from $335.00 to $280.00 and set an "equal weight" rating for the company in a report on Friday, January 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Leerink Partners decreased their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $314.09.

Amgen Stock Performance

Shares of AMGN stock traded up $5.08 on Friday, hitting $303.01. The company's stock had a trading volume of 3,260,757 shares, compared to its average volume of 3,124,757. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a market capitalization of $162.78 billion, a PE ratio of 40.13, a PEG ratio of 2.55 and a beta of 0.56. The stock's 50 day moving average is $275.62 and its 200-day moving average is $300.75. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts expect that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.14%. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares in the company, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock valued at $10,410,596 over the last quarter. 0.69% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.